Sensei to ditch its lead candidate and cut workforce amidst strategic review
The Boston-based biotech is axing Phase II plans for its only clinical-stage asset, in a bid to maximise shareholder value.
Immuno
Teva to collaborate with Fosun Pharma for TEV-56278
EHA 2025: AstraZeneca’s surovatamig is potential next-gen BiTE for R/R B-ALL
NICE approves GSK’s belantamab mafodotin for blood cancer
Antares Therapeutics gains $177m for cancer medicines development
ASH 2024: Regeneron’s Ordspono faces challenges, but positive results signal hope
Merus’ Bizengri granted FDA accelerated approval to treat NRG1+ cancers
NCCN visits Vietnam in continued cancer care collaboration
